Phaseline

Companies › Hinge Bio

Hinge Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Immunology, Other; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HB2198
Tetravalent bispecific anti-CD19/CD20 antibody with dual Fc domains
CD19, CD20Phase 1Healthy Volunteer; Systemic Lupus Erthematosus (SLE)Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07439263HB2198Phase 1Healthy VolunteerOtherAug 2026
NCT07491900HB2198Phase 1Systemic Lupus Erthematosus (SLE)ImmunologyOct 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CD19 (1) CD20 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech AstraZeneca Allogene Therapeutics Miltenyi Biomedicine Roche Lyell Immunopharma Amgen Beijing Yongtai Ruike Biotechnology Company

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.